The departure of three directors signals board refreshment, not distress, as all cited retirements. However, the broad option repricing suggests significant stock price decline has undermined equity incentives. Traders should monitor upcoming earnings and R&D updates for signs of execution risk or progress. The retention structure implies management expects volatility ahead.
Price Chart
Executive Summary
Pliant Therapeutics announced the retirement of three board members effective at the 2026 Annual Meeting and a broad stock option repricing to $1.33 per share for employees, including executives, to retain talent during a critical phase. The repricing is contingent on continued service through a defined retention period.
Key Facts
- Three independent directors — David E.I. Pyott, Katharine Knobil, M.D., and Suzanne Bruhn, Ph.D. — notified the company of their retirement from the board and all committees, effective at the 2026 Annual Meeting.
- The board approved a stock option repricing for all employee-held options granted on or before March 1, 2025, including those held by executive officers.
- The new exercise price is $1.33 per share, the closing price on the effective date (April 17, 2026), down from higher underwater prices.
- Eligible participants, including the CEO, CFO, CHRO, and COO, must remain employed through a retention period (12 or 18 months) to benefit from the repricing.
- The company stated that all employee options were underwater as of the approval date.
Financial Impact
No immediate cash impact, but potential future dilution is avoided by repricing instead of issuing new equity. The move preserves cash by not requiring additional compensation.
Risk Factors
- Option repricing may be viewed negatively by shareholders as rewarding underperformance.
- Loss of experienced board members could reduce governance stability during a critical phase.
- If the stock does not recover above $1.33, the repricing may fail to retain key talent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001746473-26-000050 |
| Document: 0001746473-26-000050-index-headers.html | 0001746473-26-000050 |
| Document: 0001746473-26-000050-index.html | 0001746473-26-000050 |
| Document: 0001746473-26-000050.txt | 0001746473-26-000050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | Press Release | $1.15 $1.15 | ▼ −0.43% | ▲ +0.55% | $1.03 (−10.43%) |
May 11, 2026 20w ago | 8-K | $1.18 $1.16 | ▼ −1.69% | ▲ +0.03% | $1.03 (−12.71%) |
May 11, 2026 20w ago | Press Release | $1.18 $1.16 | ▲ +1.69% | ▼ −0.03% | $1.03 (+12.71%) |
Apr 17, 2026 23w ago | 8-K | $1.29 $1.18 | ▼ −8.53% | ▼ −12.73% | $1.03 (−20.16%) |
Apr 7, 2026 25w ago | EFFECT | $1.31 $1.19 | ▼ −9.16% | ▼ −18.94% | $1.03 (−21.37%) |
Mar 11, 2026 29w ago | 8-K | $1.41 $1.28 | ▼ −9.22% | ▼ −11.19% | $1.03 (−26.95%) |
Mar 3, 2026 30w ago | 8-K | $1.29 $1.32 | ▲ +2.33% | ▲ +6.74% | $1.03 (−20.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access